Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.7391
-0.0330-4.27%
Volume:2.19M
Turnover:1.64M
Market Cap:166.08M
PE:-1.52
High:0.7869
Open:0.7613
Low:0.7247
Close:0.7721
Loading ...

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
19 Dec 2024

Sangamo Shares Rally Premarket on License Deal With Astellas

Dow Jones
·
19 Dec 2024

Sangamo Grants Capsid License to Astellas for Neurological Disease Targets

MT Newswires Live
·
19 Dec 2024

BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement

Reuters
·
19 Dec 2024

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

THOMSON REUTERS
·
19 Dec 2024

Sangamo Therapeutics Inc - to Receive $20 Million Upfront License Fee

THOMSON REUTERS
·
19 Dec 2024

Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments

THOMSON REUTERS
·
19 Dec 2024

Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7

MT Newswires Live
·
13 Dec 2024

Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment

THOMSON REUTERS
·
20 Nov 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

Simply Wall St.
·
20 Nov 2024

BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment

Reuters
·
20 Nov 2024

Sangamo Therapeutics Shares up 12.2% Premarket After FDA Clears Application to Start Trial for Pain Treatment

THOMSON REUTERS
·
20 Nov 2024

BRIEF-Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503

Reuters
·
20 Nov 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment

Dow Jones
·
20 Nov 2024

Sangamo gets FDA clearance of IND application for ST-503 in iSFN

TIPRANKS
·
20 Nov 2024

Sangamo up 11% at $2.17 on FDA clearing IND for ST-503

TIPRANKS
·
20 Nov 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

THOMSON REUTERS
·
20 Nov 2024

Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025

THOMSON REUTERS
·
20 Nov 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Business Wire
·
20 Nov 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
15 Nov 2024